Trial Profile
A Pilot Phase 2 Study of Albumin-bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 17 May 2021 Status changed from completed to discontinued.
- 26 Feb 2021 Status changed from active, no longer recruiting to completed.
- 21 Jan 2021 Planned End Date changed from 1 Nov 2021 to 1 Feb 2021.